Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System
- Conditions
- Interventions
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2024-05-01
- Target Recruit Count
- 208
- Registration Number
- NCT03495960
- Locations
- 🇫🇮
Tampere University Hospital, Tampere, Finland
🇮🇱Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
🇮🇹Ospedale C.e G. Mazzoni, Ascoli Piceno, Italy
Short Course Daratumumab in Patients With Multiple Myeloma
- First Posted Date
- 2018-04-06
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT03490344
- Locations
- 🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT03477539
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 295
- Registration Number
- NCT03433001
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 45
- Registration Number
- NCT03416374
- Locations
- 🇯🇵
Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵Kyorin University Hospital, Mitaka, Tokyo, Japan
🇯🇵Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 265
- Registration Number
- NCT03412565
- Locations
- 🇺🇸
Cancer Center of Central Connecticut - Southington, Southington, Connecticut, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Avera Medical Group - Oncology & Hematology, Sioux Falls, South Dakota, United States
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2023-03-29
- Target Recruit Count
- 18
- Registration Number
- NCT03411031
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
- Conditions
- Primary Cutaneous Anaplastic Large Cell LymphomaStage III Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage I Cutaneous T-Cell Non-Hodgkin LymphomaLymphomatoid PapulosisStage IV Cutaneous T-Cell Non-Hodgkin LymphomaStage II Cutaneous T-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- John Reneau
- Target Recruit Count
- 26
- Registration Number
- NCT03409432
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
- Conditions
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT03379051
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Cleveland, Ohio, United States
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
- Conditions
- Interventions
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 54
- Registration Number
- NCT03376477
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.